Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 1/20 | 0.58 |
| ▸ | ESR1 | P03372 | 11/20 | 0.54 |
| ▸ | AR | P10275 | 5/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | PGR | P06401 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | DRD1 | P21728 | 1/20 | 0.54 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methestrol SCHEMBL31290837 | 1.00 | SHBG (0.58) | SHBGESR1ARALOX15TDP1 | |
| SCHEMBL21983353 | 0.90 | SHBG (0.49) | SHBGESR1ARALOX15TDP1 | |
| SCHEMBL6260738 | 0.83 | ESR1 (0.48) | SHBGESR1ARALOX15TDP1 | |
| SCHEMBL31545996 | 0.83 | PTGS1 (0.61) | SHBGESR1ARALOX15TDP1 | |
| SCHEMBL529617 | 0.83 | ESR1 (0.48) | ESR1ARALOX15TDP1PTGS1 | |
| SCHEMBL29459520 | 0.83 | ESR1 (0.48) | ESR1ARALOX15TDP1PTGS1 | |
| SCHEMBL13698041 | 0.82 | CYP3A4 (0.47) | ESR1ARTDP1LMNACYP1A2 | |
| SCHEMBL97663 | 0.82 | GAA (0.65) | ESR1ARALOX15TDP1LMNA | |
| SCHEMBL5709894 | 0.80 | ESR1 (0.46) | SHBGESR1ARALOX15TDP1 | |
| SCHEMBL217919 | 0.78 | TP53 (0.54) | ESR1ARALOX15TDP1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 492 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2022182523-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2021158573-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| WO-2021158575-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20110003748-A1 | Method of treatment and compositions of D-chiro inositol and phosphates thereof | JENNINGS-SPRING BARBARA L | 2011-01-06 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| US-20090214474-A1 | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development | JENNINGS BARBARA BROOKE | 2009-08-27 | — | — | US | claimed |
| WO-2005065185-A2 | TEMPERATURE-STABLE FORMULATIONS, AND METHODS OF DEVELOPMENT THEREOF | COLLEGIUM PHARMACEUTICALS, INC. (US) | 2005-07-21 | — | — | WO | claimed |
| US-20050153946-A1 | Temperature-stable formulations, and methods of development thereof | COLLEGIUM PHARMACEUTICALS, INC. (US) | 2005-07-14 | — | — | US | claimed |
| EP-1443939-A1 | COMPOSITIONS FOR TREATMENT OF POSTMENOPAUSAL FEMALE SEXUAL DYSFUNCTION | Pharmacia Corporation (US) | 2004-08-11 | — | — | EP | claimed |
| US-20030130244-A1 | Compositions for treatment of postmenopausal female sexual dysfunction | PHARMACIA CORPORATION | 2003-07-10 | — | — | US | claimed |
| WO-2003039553-A1 | COMPOSITIONS FOR TREATMENT OF POSTMENOPAUSAL FEMALE SEXUAL DYSFUNCTION | PHARMACIA CORPORATION (US) | 2003-05-15 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0046270-B1 | NOVEL DERIVATIVES OF BIO-AFFECTING PHENOLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | INTERx RESEARCH CORPORATION (US) | 1986-05-21 | — | — | EP | claimed |
| EP-0046270-A1 | Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them | INTERx RESEARCH CORPORATION (US) | 1982-02-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | SHBG 67/4885ESR1 1524/4885AR 1999/4885 |
| US-20110003748-A1 | Method of treatment and compositions of D-chiro inositol and phosphates thereof | PPIP5K2, SHBG, CYP24A1 | SHBG 2/4885ESR1 468/4885AR 853/4885 |
| US-20090214474-A1 | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development | SHH, ERH, CDK5 | SHBG 2076/4885ESR1 903/4885AR 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.